{
    "nctId": "NCT03177902",
    "briefTitle": "Evaluation of Thyroid Abnormity Incidence and Thyroid Toxicity During Chemotherapy Among Newly Diagnosed Breast Cancer",
    "officialTitle": "A Prospective Study to Assess Both Thyroid Abnormity Incidence In Chinese Women With Newly Diagnosed Breast Cancer and Thyroid Toxicity of Breast Cancer Patients Undergoing Chemotherapy",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer Female, Thyroid Gland",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 400,
    "primaryOutcomeMeasure": "Number of participants newly diagnosed with breast cancer",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Female patients with histologically or cytologically proven primary breast cancer;\n2. Age \\>18 years;\n3. ECOG Performance Status: 0-2;\n4. Life Expectancy: 3 months or more;\n5. No previous anti-cancer therapy;\n6. Be willing to undergo at least four cycles of anthracycline or taxane-based chemotherapy;\n7. Adequate hematological, liver, and kidney functions.\n\nExclusion Criteria:\n\n1. Pregnancy or lactation;\n2. History of other malignancy or secondary breast cancer;\n3. History of thyroid disease;\n4. History of drug addiction or abuse;\n5. History of immunodeficiency disease;\n6. Treatment with drugs capable of influencing thyroid gland functions within 3 months prior to study entry;\n7. Nonmeasurable disease such as un-controlled diabetes, severe cardiovascular and cerebrovascular diseases;\n8. Current, recent (within 4 weeks prior to study entry), or planned participation in any other clinical trials;\n9. Inability to understand and agree to informed consent.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}